SCHEMBL18594591

SCHEMBL18594591

CC(C)(C)Cc1ccc2c(c1)OCCN2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.45
GAA P10253 2/20 0.45
HSD17B10 Q99714 2/20 0.45
MAPT P10636 1/20 0.45
TRPV1 Q8NER1 2/20 0.41
GRM2 Q14416 1/20 0.39
GRM5 P41594 1/20 0.37
KDM4E B2RXH2 1/20 0.37
GLA P06280 1/20 0.37
HPGD P15428 1/20 0.37
CASP1 P29466 1/20 0.37
CASP7 P55210 1/20 0.37
ATM Q13315 1/20 0.37
HDAC11 Q96DB2 1/20 0.36
PIK3CA P42336 1/20 0.35
AR P10275 1/20 0.35
ESR1 P03372 1/20 0.34
AURKA O14965 1/20 0.34
QPCT Q16769 1/20 0.34
EGFR P00533 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22210654 0.88 ALDH1A1 (0.57) ALDH1A1GAAHSD17B10MAPTTRPV1
SCHEMBL22356713 0.84 ESR1 (0.36) GAAESR1
SCHEMBL19772859 0.83 ALDH1A1 (0.46) ALDH1A1GAAHSD17B10MAPTTRPV1
SCHEMBL764037 0.82 ALDH1A1 (0.49) ALDH1A1GAAHSD17B10MAPTTRPV1
SCHEMBL20306282 0.80 FABP6 (0.47) ALDH1A1GAAHSD17B10MAPTGRM5
SCHEMBL22912275 0.79 ALDH1A1 (0.45) ALDH1A1GAAHSD17B10MAPTTRPV1
SCHEMBL25107140 0.78 ALDH1A1 (0.45) ALDH1A1GAAHSD17B10MAPTTRPV1
SCHEMBL18522454 0.78 ALDH1A1 (0.45) ALDH1A1GAAHSD17B10MAPTTRPV1
SCHEMBL7767339 0.76 CYP2D6 (0.46) ALDH1A1GAAHSD17B10MAPTTRPV1
SCHEMBL18583849 0.76 S1PR1 (0.36) ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11007193-B2 2,4-pyrimidinediamine compounds and their uses RIGEL PHARMACEUTICALS, INC. (US) 2021-05-18 US disclosed
US-10682350-B2 2,4-pyrimidinediamine compounds and their uses RIGEL PHARMACEUTICALS, INC. (US) 2020-06-16 US disclosed
US-10314840-B2 2,4-pyrimidinediamine compounds and their uses RIGEL PHARMACEUTICALS, INC. (US) 2019-06-11 US disclosed
US-20170362180-A1 QUINOLONE COMPOUND OTSUKA PHARMA CO LTD (JP) 2017-12-21 US disclosed
US-20170246167-A1 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES RIGEL PHARMACEUTICALS, INC. (US) 2017-08-31 US disclosed
US-9586908-B2 2,4-pyrimidinediamine compounds and their uses RIGEL PHARMACEUTICALS, INC. (US) 2017-03-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170362180-A1 QUINOLONE COMPOUND HAX1, NQO2, NHERF1 ALDH1A1 1445/4885GAA 3410/4885HSD17B10 640/4885
US-20170246167-A1 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES FCER2, FCGR1A, FCGR2A ALDH1A1 2891/4885GAA 2220/4885HSD17B10 4781/4885
US-10682350-B2 2,4-pyrimidinediamine compounds and their uses FCER2, FCGR1A, FCGR2A ALDH1A1 2891/4885GAA 2220/4885HSD17B10 4781/4885
US-10314840-B2 2,4-pyrimidinediamine compounds and their uses FCER2, FCGR1A, FCGR2A ALDH1A1 2891/4885GAA 2220/4885HSD17B10 4781/4885
US-11007193-B2 2,4-pyrimidinediamine compounds and their uses FCER2, FCGR1A, FCGR2A ALDH1A1 2891/4885GAA 2220/4885HSD17B10 4781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.